FMP
Nymox Pharmaceutical Corporation
NYMX
NASDAQ
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia, and Phase II clinical trials for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. In addition, it offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease, as well as researches and develops drug treatments for Alzheimer's disease. The company was founded in 1989 and is headquartered in Nassau, the Bahamas.
0.2 USD
-0.0001 (-0.05003%)
About
ceo
Dr. Paul Averback DABP, M.D.
sector
Healthcare
industry
Biotechnology
website
https://nymox.com
exchange
NASDAQ
Description
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia, and Phase II clinical trials for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. In addition, it offers AlzheimAlert, a proprietary urine assay that aids physician...
CIK
0001018735
ISIN
BSP733981026
CUSIP
P73398102
Address
Bay & Deveaux Streets
Phone
18009369669
Country
BS
Employee
3
IPO Date
Nov 26, 1997
Summary
CIK
0001018735
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
P73398102
ISIN
BSP733981026
Country
BS
Price
0.2
Beta
0.82
Volume Avg.
134.78k
Market Cap
18.24M
Shares
-
52-Week
0.17-0.74
DCF
1.27
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-2.86
P/B
-
Website
https://nymox.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest NYMX News
It looks like there's no news available.
